These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 23833065

  • 1. Improved anti-inflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide.
    Sabzevari A, Adibkia K, Hashemi H, De Geest BG, Mohsenzadeh N, Atyabi F, Ghahremani MH, Khoshayand MR, Dinarvand R.
    Invest Ophthalmol Vis Sci; 2013 Aug 15; 54(8):5520-6. PubMed ID: 23833065
    [Abstract] [Full Text] [Related]

  • 2. Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies.
    Sabzevari A, Adibkia K, Hashemi H, Hedayatfar A, Mohsenzadeh N, Atyabi F, Ghahremani MH, Dinarvand R.
    Eur J Pharm Biopharm; 2013 May 15; 84(1):63-71. PubMed ID: 23295645
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
    Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J, Csaky KG.
    Exp Eye Res; 2006 Mar 15; 82(3):479-87. PubMed ID: 16168412
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis.
    Shin JP, Park YC, Oh JH, Lee JW, Kim YM, Lim JO, Kim SY.
    J Ocul Pharmacol Ther; 2009 Jun 15; 25(3):201-8. PubMed ID: 19456254
    [Abstract] [Full Text] [Related]

  • 7. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
    Chen M, Li X, Liu J, Han Y, Cheng L.
    J Control Release; 2015 Apr 10; 203():109-17. PubMed ID: 25700623
    [Abstract] [Full Text] [Related]

  • 8. Biodegradable scleral implants as new triamcinolone acetonide delivery systems.
    Felt-Baeyens O, Eperon S, Mora P, Limal D, Sagodira S, Breton P, Simonazzi B, Bossy-Nobs L, Guex-Crosier Y, Gurny R.
    Int J Pharm; 2006 Sep 28; 322(1-2):6-12. PubMed ID: 16824708
    [Abstract] [Full Text] [Related]

  • 9. RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.
    Kadam RS, Tyagi P, Edelhauser HF, Kompella UB.
    Int J Pharm; 2012 Sep 15; 434(1-2):140-7. PubMed ID: 22633904
    [Abstract] [Full Text] [Related]

  • 10. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation.
    Kesavan K, Kant S, Singh PN, Pandit JK.
    Curr Eye Res; 2013 Mar 15; 38(3):342-52. PubMed ID: 23216079
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
    Mruthyunjaya P, Khalatbari D, Yang P, Stinnett S, Tano R, Ashton P, Guo H, Nazzaro M, Jaffe GJ.
    Arch Ophthalmol; 2006 Jul 15; 124(7):1012-8. PubMed ID: 16832025
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of controlled-release triamcinolone acetonide-loaded mPEG-PLGA nanoparticles in treating experimental autoimmune uveitis.
    Guo D, Li Q, Sun Y, Guo J, Zhao Q, Yin X, Wei H, Wu S, Bi H.
    Nanotechnology; 2019 Apr 19; 30(16):165702. PubMed ID: 30641491
    [Abstract] [Full Text] [Related]

  • 13. Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis.
    Singh RP, Mathews ME, Kaufman M, Riga A.
    Br J Ophthalmol; 2010 Feb 19; 94(2):170-3. PubMed ID: 20139290
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract.
    Dada T, Dhawan M, Garg S, Nair S, Mandal S.
    J Cataract Refract Surg; 2007 Sep 19; 33(9):1613-8. PubMed ID: 17720079
    [Abstract] [Full Text] [Related]

  • 15. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles.
    Gilger BC, Abarca EM, Salmon JH, Patel S.
    Invest Ophthalmol Vis Sci; 2013 Apr 03; 54(4):2483-92. PubMed ID: 23532526
    [Abstract] [Full Text] [Related]

  • 16. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration.
    Zarei-Ghanavati S, Malaekeh-Nikouei B, Pourmazar R, Seyedi S.
    J Ocul Pharmacol Ther; 2012 Oct 03; 28(5):502-6. PubMed ID: 22537291
    [Abstract] [Full Text] [Related]

  • 17. Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation.
    Huang J, Yu X, Zhou Y, Zhang R, Song Q, Wang Q, Li X.
    Int J Pharm; 2018 Nov 15; 551(1-2):223-231. PubMed ID: 30213683
    [Abstract] [Full Text] [Related]

  • 18. Intraocular availability of triamcinolone acetonide after intravitreal injection.
    Jonas JB.
    Am J Ophthalmol; 2004 Mar 15; 137(3):560-2. PubMed ID: 15013884
    [Abstract] [Full Text] [Related]

  • 19. A new drug delivery system inhibits uveitis in an animal model after cataract surgery.
    Eperon S, Rodriguez-Aller M, Balaskas K, Gurny R, Guex-Crosier Y.
    Int J Pharm; 2013 Feb 25; 443(1-2):254-61. PubMed ID: 23291445
    [Abstract] [Full Text] [Related]

  • 20. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application.
    Shen L, You Y, Sun S, Chen Y, Qu J, Cheng L.
    Ophthalmology; 2010 Dec 25; 117(12):2365-71. PubMed ID: 20678801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.